Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity

Jia, Wentao; Wang, Lina

doi:10.1155/2020/9843486

Cited by 22 publications

(17 citation statements)

References 115 publications

(129 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies indicated that cancer patients with TCM deficiency syndrome have lower immune function and shorter survival time, while cancer patients with excess syndrome have better immune function and longer survival time, which supports the finding of our study [ 9 ]. Also, TCM can promote the antitumor effect by restoring immunosurveillance, including upregulating immunostimulatory factors and downregulating immunosuppressive factors [ 25 ]. Besides, compared with conventional therapies of cancer-associated symptoms, the incidence of related adverse events was not increased in the TCM groups [ 26 ], and a prospective cohort study showed that TCM prescriptions were safe and tolerable to most cancer patients [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology

Wei

Wang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. In traditional Chinese medicine (TCM), TCM syndrome is a key guideline, and Chinese materia medicas are widely used to treat hepatitis B virus- (HBV-) related hepatocellular carcinoma (HCC) according to different TCM syndromes. However, the prognostic value of TCM syndromes in HBV-related HCC patients has never been studied. Methods. A retrospective cohort of HBV-related HCC patients at Shenzhen Traditional Chinese Medicine Hospital from December 2005 to October 2017 was analyzed. The prognostic value of TCM syndromes in HBV-related HCC patients was assessed by Kaplan–Meier survival curves and Cox analysis, and the TCM syndrome with the best prognosis of HBV-related HCC patients was determined. To further study the relevant mechanisms, key Chinese materia medicas (KCMMs) for the TCM syndrome with the best prognosis were summarized, and network pharmacology was also performed. Results. A total of 207 HBV-related HCC patients were included in this research, and we found that HBV-related HCC patients with TCM excess syndrome had better OS. Then, a total of eight KCMMs for TCM excess syndrome were identified, whose crucial ingredients included quercetin, beta-sitosterol, kaempferol, luteolin, and XH-14, and KCMMs could play a therapeutic role through MAPK, JAK-STAT, Wnt, Hippo, and other pathways. Moreover, TP53, SRC, STAT3, MAPK3, PIK3R1, HRAS, VEGFA, HSP90AA1, EGFR, and JAK2 were determined as the key targets. Conclusion. We propose a new research method of “prognosis of TCM syndromes-KCMMs-network pharmacology” to reveal the prognostic value of TCM syndromes and the potential mechanism by which TCM syndromes affect prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology

Wei

Wang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…A meta-analysis showed that TCM treatment improves the immune response for unresectable HCC after TACE treatment ( Meng et al, 2011 ). TCM is gathering increasing interest due to the immunoregulatory properties of certain compounds which can restore immunosurveillance in HCC to promote anti-tumor effects in several pathways, including the upregulation of immunostimulatory factors and the downregulation of immunosuppressive factors ( Jia and Wang, 2020 ). Several clinical studies have demonstrated that the utility of TCM can reduce adverse events after the TACE treatment of HCC patients.…”

Section: Discussionmentioning

confidence: 99%

Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine

Zhou

Liu

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) accounts for 70–85% of liver cancer, and about 85% of HCC are hepatitis B virus-related (HBV-HCC) in China. Transarterial chemoembolization (TACE) combined with traditional Chinese medicine (TCM) has been reported as an effective treatment. Potential biomarkers to stratify patients who may benefit from this treatment are needed. In this study, we aimed to evaluate whether circulating cell-free mitochondrial DNA (ccf-mtDNA) content was associated with the outcome of HCC patients, especially of those who received the combination treatment of TACE and TCM. Univariate and multivariate Cox analyses were conducted to evaluate the association between ccf-mtDNA content and the overall survival of HBV-HCC patients. Kaplan–Meier analysis was used to compare the survival differences between patients with low and high ccf-mtDNA content. In a hospital-based cohort with 141 HBV-HCC patients, there was no statistically significant association between the ccf-mtDNA content and the overall survival of HBV-HCC patients in the univariate analysis, but a borderline significant association was found in the multivariate analyses. In a subcohort of 50 HBV-HCC patients who received TACE and TCM treatment, high ccfDNA content conferred an increased death risk with a hazard ratio of 4.01 (95% confidence interval: 1.25–12.84, p = 0.019) in the multivariate analysis. Kaplan–Meier survival analysis also showed that patients with high ccf-mtDNA content had unfavorable survival (log rank p = 0.097). Our findings suggest that ccf-mtDNA content is a potential non-invasive prognostic biomarker in HCC patients receiving TACE and TCM treatment.

show abstract

“…Meta-analysis showed Traditional Chinese Medicine (TCM) improves immune response for unresectable hepatocellular carcinoma (UHCC) after transcatheter arterial chemoembolization (TACE) 21 . TCM is gathering increasing interest due to the immunoregulatory properties of certain compounds, it can restore immunosurveillance in HCC to promote anti-tumor effects in several ways, including the upregulation of immunostimulatory factors and the downregulation of immunosuppressive factors 22 . And also clinical studies have demonstrated the utility of TCM in relieving adverse events after TACE, Tang et al found the chinese medicine Jianpi Ligan decoction (JLD) was effective for reduction of side effects and improvement of long-term survival for patients with unresectable HCC treated by TACE 23 .…”

Section: Discussionmentioning

confidence: 99%

Circulating cell-free mtDNA content is associated with outcome of HCC patients receiving TACE combined with traditional Chinese medicine treatment

Zhou

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives: Hepatocellular carcinoma (HCC) accounts for 70%-85% of liver cancer, and about 85% of HCC are hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) in china. Most patients are already in the middle or late stages of the disease at the time of diagnosis, trans-hepatic arterial chemoembolization (TACE) combine with traditional Chinese medicine (TCM) have been reported as an effective treatment, and effective prognostic molecular markers are helpful to predict therapeutic efficacy. In this study, we aim to explore whether circulating cell-free mitochondrial DNA (ccf-mtDNA) content is associated with the outcome for HCC patients receiving TACE combine with TCM treatment. Method: Retrospective analysis was conducted in a cohort with 141 HBV-HCC patients. Univariate and multivariate analysis was conducted with Cox proportional risk regression model to explore the correlation between ccf-mtDNA content and patient prognosis. Kaplan-Meier method was used to draw the survival curve of ccf-mtDNA content and the survival prognosis of patients. Results: (1) high content of serum ccf-mtDNA is an independent risk factor for the prognosis of HBV-HCC patients treated with TACE combined with TCM adjuvant therapy (HR=4.010, 95%IC=1.252-12.844, P = 0.019). (2) K-M survival analysis showed that patients with high ccf-mtDNA content had poor prognosis (Log Rank P=0.027). Conclusions: Our findings suggest that ccf-mtDNA is a potential novel non-invasive biomarker for prognosis of HCC patients receiving TACE combine with TCM treatment.

show abstract

Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity

Cited by 22 publications

References 115 publications

Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology

Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology

Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine

Circulating cell-free mtDNA content is associated with outcome of HCC patients receiving TACE combined with traditional Chinese medicine treatment

Contact Info

Product

Resources

About